Currently included on this page are:
BIA CSC Position Statement on the determination of Consultant Competence
Tackling antimicrobial resistance - educational priorities
NCEPOD - call for study proposals
UK SMI V 4: investigation of hepatitis B infection
SaBTO Microbiological Safety Guidelines
Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C
2018 National AMR Campaign
Healthcare professional survey - pharma communications strategies
Immediate ART for treatment of HIV-1 in adults and adolescent
We note that RCPath have also produced a position statement which was published on 10/07/2017. Both documents are entirely congruent.
This document was updated in January 2018; the updated version is available below.
In 2017 Health Education England committed to work with stakeholders to explore the factors that help or hinder education about antimicrobial resistance and to identify good practice materials for promotion. We asked those that train healthcare workers what works well in an educational environment, what the challenges are and how Health Education England might support the education of prudent, responsible use of antimicrobials
The report Tackling antimicrobial resistance – educational priorities explores perspectives about educational interventions that may help address antimicrobial resistance in different healthcare settings and barriers for implementation.
The themes in this report will inform the future direction of Health Education England’s antimicrobial resistance and sepsis programme.
NCEPOD's 2018 call for study proposals is open until 5th October 2018. We are inviting organisations to submit original study proposals, which will be considered as possible forthcoming studies. Study proposals should be relevant to the current clinical environment and, very importantly, should have the potential to contribute original work to the subject.
The last full scientific review of this document was completed on 7th June 2018.
Click for further information
A new revision of the guide to the microbiological safety of human organs, tissues and cells used in transplantation, now renamed as the SaBTO microbiological safety guidelines, has been published. The new guidelines are available on the SaBTO website.
NICE technology appraisal TA361 on simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) has been withdrawn because Janssen withdrew the marketing authorisation for simeprevir on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
The 2018 National AMR campaign was launched in March, and will run until September 2018.
This is a highly targeted national AMR awareness and educational campaign titled “Drug Resistance” in partnership with ESCMID, BIVDA and BSAC reaching key stakeholders such as Clinical Microbiologists, Government, CCG’s and the public. Details of the campaign, and its aim are below.
Campaign title: 2018 Drug Resistance (AMR)
Launch date: 9th of March running until September 2018
Format: Multi- platform campaign: 16-page print publication in the Guardian, online via www.globalcause.co.uk, events, conferences and via social media
Aim: To provide an educational, action and implementation campaign around antimicrobial resistance and the need to preserve the effectiveness of antibiotics
Target Audience: HCP’s (Clinical and non- clinical), Investors, policy makers, Industry and the public
Further information is available at www.globalcause.co.uk
Do you want to influence how you communicate with Pharma?
This survey is around pharma’s relationship with doctors and what they feel is appropriate / optimal in terms of content / channel of communication. The idea is to raise awareness in the pharmaceutical industry of how doctors want to be communicated with. The results of the survey will be published in the pharmaceutical press (pharmaphorum) as well as circulated through industry contacts. This is an opportunity for doctors to have a say in the way that they communicate with the pharma industry and should hopefully help to stimulate meaningful debate at a time where the relationship is somewhat strained.
Virtual Doctors is a small charity which provides email advice to rural health workers in Africa and is currently looking to recruit more volunteer doctors (especially infectious diseases) based in the UK. Anyone interested in helping - particularly trainees, as this may be a good learning opportunity - should refer to the Virtual Doctors website for more information.